|Mr. James V. Caruso||Pres, CEO & Director||807.5k||N/A||1959|
|Mr. Dov Elefant||VP & CFO||450.99k||N/A||1967|
|Mr. Jarrod Longcor||Chief Bus. Officer||491.01k||N/A||1973|
|Dr. John E. Friend II, M.D.||Chief Medical Officer||N/A||N/A||1970|
|Gregory J. Lynch Esq.||Sec.||N/A||N/A||N/A|
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; and IntoCell Inc. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.